14-Jul-2005
Novel non-hydroxamic histone deactylase (HDAC) inhibitors in development from Miikana
Summary
The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile
Last Updated: 27-Aug-2010
The field of histone deacetylase inhibitors is moving into a new phase of development. LeadDiscovery's report on Histone deacetylase inhibitors highlights the biology of the HDACs and the potential of their inhibitors. In profiling the various HDAC inhibitors in development we discuss the toxicological risk of hydroxamic acid, a moiety found in early inhibitors including SAHA. Our strategic evaluation discusses the development of HDAC inhibitors in which the hydroxamic acid has been replaced by other moieties. Here we highlight a series of mercaptoamides being developed by Miikana...[more]
Source LeadDiscovery
Featured on DailyUpdates-Oncology
